董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anders Hove | 男 | Director | 58 | 15.00万美元 | 未持股 | 2024-01-22 |
| James Flynn | 男 | Director | 44 | 4.00万美元 | 未持股 | 2024-01-22 |
| Jacob Ma Weaver | 男 | Director | 37 | 13.00万美元 | 未持股 | 2024-01-22 |
| Linda Grais | 女 | Director | 67 | 16.25万美元 | 未持股 | 2024-01-22 |
| Michael R. Bristow | 男 | President and Chief Executive Officer and Director | 79 | 35.88万美元 | 未持股 | 2024-01-22 |
| Robert E. Conway | 男 | Director, Chairman | 70 | 19.50万美元 | 未持股 | 2024-01-22 |
| Dan J. Mitchell | 男 | Director | 67 | 5.25万美元 | 未持股 | 2024-01-22 |
| Raymond L. Woosley | 男 | Director | 81 | 5.50万美元 | 未持股 | 2024-01-22 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas A. Keuer | 男 | Chief Operating Officer | 65 | 40.08万美元 | 未持股 | 2024-01-22 |
| Michael R. Bristow | 男 | President and Chief Executive Officer and Director | 79 | 35.88万美元 | 未持股 | 2024-01-22 |
| C. Jeffrey Dekker | 男 | Chief Financial Officer | 59 | 32.31万美元 | 未持股 | 2024-01-22 |
董事简历
中英对照 | 中文 | 英文- Anders Hove
-
Anders Hove自2017年2月起担任董事会成员。Hove博士是Acorn BioVentures的经理，这是一家专注于生物技术、专业制药和医疗设备公司的长期投资的合伙企业。Hove博士最近于2017年至2019年担任Amzak Health的管理合伙人，在此之前，他是风险投资公司Venrock Associates的普通合伙人，他于2004年加入该公司，并一直担任到2016年。2008年，Hove博士是Venrock Healthcare Capital Partners，Venrock&；8217；的公共基金的创始人，该基金专注于小型生物技术公司和后期私人公司。Hove从1996年到2004年担任BB Biotech Fund（一家投资公司）基金经理，从2002年到2003年担任Bellevue Asset Management，LLC（一家投资公司）首席执行官。Hove博士此前曾在Ciba-Geigy和Novartis的制药部门的医疗、临床和业务运营担任高级职位。Hove先生自2005年起担任Anacor Pharmaceuticals（一家上市制药公司）的董事会成员，直到2016年6月被辉瑞（Pfizer）收购，并于2015年至2016年被Edge Therapeutics（一家上市生物技术公司）收购。此外，Hove博士是MC2Therapeutics的董事会成员。他获得了理学硕士学位。丹麦技术大学生物技术工程学士学位，哥本哈根大学医学博士学位和欧洲行政管理学院工商管理硕士学位。
Anders Hove,has served as a member of the Board of Directors since February 2017. Dr. Hove is the manager of Acorn Bioventures, a partnership focusing on long-term investments in biotech, specialty pharma and medical device companies. Before Dr. Hove was a general partner of Venrock Associates, a venture capital firm, which he joined in 2004 and remained at through 2016. In 2008, Dr. Hove was a founder of Venrock Healthcare Capital Partners, Venrock's public funds focused on small capitalization biotech companies and late-stage private companies. From 1996 to 2004, Dr. Hove was a fund manager at BB Biotech, an investment firm, and from 2002 to 2003 he also served as Chief Executive Officer of Bellevue Asset Management, an investment company. Dr. Hove previously held senior level positions in the medical, clinical and business operations of the pharmaceuticals division of Ciba-Geigy and Novartis. Mr. Hove was a member of the boards of directors of Anacor Pharmaceuticals, a publicly traded pharmaceutical company, from 2005 until its acquisition by Pfizer in June 2016, and Edge Therapeutics, a publicly traded biotechnology company, from 2015 to 2016. In addition, Dr. Hove is a member of the board of directors of MC2 Therapeutics. He received a M.Sc. in Biotechnology Engineering from the Technical University of Denmark, an M.D. from the University of Copenhagen and an M.B.A. from INSEAD (the Institut Européen d'Administration des Affaires). - Anders Hove自2017年2月起担任董事会成员。Hove博士是Acorn BioVentures的经理，这是一家专注于生物技术、专业制药和医疗设备公司的长期投资的合伙企业。Hove博士最近于2017年至2019年担任Amzak Health的管理合伙人，在此之前，他是风险投资公司Venrock Associates的普通合伙人，他于2004年加入该公司，并一直担任到2016年。2008年，Hove博士是Venrock Healthcare Capital Partners，Venrock&；8217；的公共基金的创始人，该基金专注于小型生物技术公司和后期私人公司。Hove从1996年到2004年担任BB Biotech Fund（一家投资公司）基金经理，从2002年到2003年担任Bellevue Asset Management，LLC（一家投资公司）首席执行官。Hove博士此前曾在Ciba-Geigy和Novartis的制药部门的医疗、临床和业务运营担任高级职位。Hove先生自2005年起担任Anacor Pharmaceuticals（一家上市制药公司）的董事会成员，直到2016年6月被辉瑞（Pfizer）收购，并于2015年至2016年被Edge Therapeutics（一家上市生物技术公司）收购。此外，Hove博士是MC2Therapeutics的董事会成员。他获得了理学硕士学位。丹麦技术大学生物技术工程学士学位，哥本哈根大学医学博士学位和欧洲行政管理学院工商管理硕士学位。
- Anders Hove,has served as a member of the Board of Directors since February 2017. Dr. Hove is the manager of Acorn Bioventures, a partnership focusing on long-term investments in biotech, specialty pharma and medical device companies. Before Dr. Hove was a general partner of Venrock Associates, a venture capital firm, which he joined in 2004 and remained at through 2016. In 2008, Dr. Hove was a founder of Venrock Healthcare Capital Partners, Venrock's public funds focused on small capitalization biotech companies and late-stage private companies. From 1996 to 2004, Dr. Hove was a fund manager at BB Biotech, an investment firm, and from 2002 to 2003 he also served as Chief Executive Officer of Bellevue Asset Management, an investment company. Dr. Hove previously held senior level positions in the medical, clinical and business operations of the pharmaceuticals division of Ciba-Geigy and Novartis. Mr. Hove was a member of the boards of directors of Anacor Pharmaceuticals, a publicly traded pharmaceutical company, from 2005 until its acquisition by Pfizer in June 2016, and Edge Therapeutics, a publicly traded biotechnology company, from 2015 to 2016. In addition, Dr. Hove is a member of the board of directors of MC2 Therapeutics. He received a M.Sc. in Biotechnology Engineering from the Technical University of Denmark, an M.D. from the University of Copenhagen and an M.B.A. from INSEAD (the Institut Européen d'Administration des Affaires).
- James Flynn
-
詹姆斯·弗林如果当选，将成为董事会成员，自2022年年会起生效。Flynn先生目前是Nerium Capital LLC的管理成员和投资组合经理，Nerium Capital LLC是他于2021年创立的投资顾问。Nerium Capital LLC是Nerium Partners LP的普通合伙人，这是一家专注于医疗保健的投资合伙企业。Flynn先生目前还担任Axiom Health的董事会成员，该公司自2022年起为医疗保健行业提供软件和大数据解决方案，并自2020年起担任该公司的顾问。2017年至2018年，弗林先生在一家投资公司Aptigon Capital a Citadel Company担任治疗分析师。在此之前，Flynn先生于2003年至2017年在投资公司Amici Capital，LLC担任过多个职务，包括医疗保健投资组合经理（2008年至2017年）。从2002年到2003年，Flynn先生在投资公司Putnam Investments的信贷研究/高收益小组工作。Flynn先生在麻省理工学院（MIT）获得管理科学学士学位，主修金融学，辅修经济科学。Flynn先生是特许金融分析师（CFA）的持证人。
James Flynn,has served as a member of the Board of Directors since December 2022. Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium Capital LLC, an investment adviser he founded in 2021. Mr. Flynn has served as a board member for Axiom Health (a provider of software and big-data solutions to the healthcare industry) since 2022, a board member for MEI Pharma, Inc (a pharmaceutical company committed to the development of novel and differentiated cancer therapies) since 2023, and joined the board of RiceBran Technologies (an innovative specialty ingredients company) in January 2024. From 2017 to 2018, Mr. Flynn worked as a therapeutics analyst at Aptigon Capital (a Citadel Company), an investment firm. Prior to that, from 2003 to 2017, Mr. Flynn served in various roles at Amici Capital, LLC, an investment firm, including healthcare portfolio manager (2008 to 2017). From 2002 to 2003, Mr. Flynn workd in the credit research/high yield group at Putnam Investments, an investment firm. Mr. Flynn earned a S.B. degree in Management Science with a concentration in Finance and a minor in Economic Science from the Massachusetts Institute of Technology (MIT). Mr. Flynn is a Chartered Financial Analyst (CFA) charterholder. - 詹姆斯·弗林如果当选，将成为董事会成员，自2022年年会起生效。Flynn先生目前是Nerium Capital LLC的管理成员和投资组合经理，Nerium Capital LLC是他于2021年创立的投资顾问。Nerium Capital LLC是Nerium Partners LP的普通合伙人，这是一家专注于医疗保健的投资合伙企业。Flynn先生目前还担任Axiom Health的董事会成员，该公司自2022年起为医疗保健行业提供软件和大数据解决方案，并自2020年起担任该公司的顾问。2017年至2018年，弗林先生在一家投资公司Aptigon Capital a Citadel Company担任治疗分析师。在此之前，Flynn先生于2003年至2017年在投资公司Amici Capital，LLC担任过多个职务，包括医疗保健投资组合经理（2008年至2017年）。从2002年到2003年，Flynn先生在投资公司Putnam Investments的信贷研究/高收益小组工作。Flynn先生在麻省理工学院（MIT）获得管理科学学士学位，主修金融学，辅修经济科学。Flynn先生是特许金融分析师（CFA）的持证人。
- James Flynn,has served as a member of the Board of Directors since December 2022. Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium Capital LLC, an investment adviser he founded in 2021. Mr. Flynn has served as a board member for Axiom Health (a provider of software and big-data solutions to the healthcare industry) since 2022, a board member for MEI Pharma, Inc (a pharmaceutical company committed to the development of novel and differentiated cancer therapies) since 2023, and joined the board of RiceBran Technologies (an innovative specialty ingredients company) in January 2024. From 2017 to 2018, Mr. Flynn worked as a therapeutics analyst at Aptigon Capital (a Citadel Company), an investment firm. Prior to that, from 2003 to 2017, Mr. Flynn served in various roles at Amici Capital, LLC, an investment firm, including healthcare portfolio manager (2008 to 2017). From 2002 to 2003, Mr. Flynn workd in the credit research/high yield group at Putnam Investments, an investment firm. Mr. Flynn earned a S.B. degree in Management Science with a concentration in Finance and a minor in Economic Science from the Massachusetts Institute of Technology (MIT). Mr. Flynn is a Chartered Financial Analyst (CFA) charterholder.
- Jacob Ma Weaver
-
Jacob Ma Weaver，于2022年6月被任命为董事会成员。他是Cable Car Capital LLC的管理成员，该公司是他于2013年创立的投资顾问。Cable Car Capital LLC是对冲基金Funicular Funds，LP的普通合伙人。2012年至2013年，Ma-Weaver先生受聘于Amici Capital LLC担任投资分析师，专注于医疗保健。此前，他曾受聘于Dodge & Cox担任股票研究助理，并在麦肯锡公司担任企业融资业务分析师。Ma-Weaver先生获得了哥伦比亚大学比较文学&社会和经济学文学学士学位和统计学文学硕士学位。他是特许金融分析师（CFA）特许持有人。
Jacob Ma Weaver,was appointed to the Board of Directors in June 2022. He is the Managing Member of Cable Car Capital LLC, an investment adviser he founded in 2013. Cable Car Capital LLC is the General Partner of Funicular Funds, LP, a hedge fund. From 2012 to 2013, Mr. MaWeaver was employed as an investment analyst at Amici Capital LLC, where he focused on healthcare. He was previously employed as an equity research associate at Dodge & Cox and a corporate finance business analyst at McKinsey & Company. Mr. Ma-Weaver received a Bachelor of Arts in Comparative Literature & Society and Economics and a Master of Arts in Statistics from Columbia University. He is a Chartered Financial Analyst (CFA) charterholder. - Jacob Ma Weaver，于2022年6月被任命为董事会成员。他是Cable Car Capital LLC的管理成员，该公司是他于2013年创立的投资顾问。Cable Car Capital LLC是对冲基金Funicular Funds，LP的普通合伙人。2012年至2013年，Ma-Weaver先生受聘于Amici Capital LLC担任投资分析师，专注于医疗保健。此前，他曾受聘于Dodge & Cox担任股票研究助理，并在麦肯锡公司担任企业融资业务分析师。Ma-Weaver先生获得了哥伦比亚大学比较文学&社会和经济学文学学士学位和统计学文学硕士学位。他是特许金融分析师（CFA）特许持有人。
- Jacob Ma Weaver,was appointed to the Board of Directors in June 2022. He is the Managing Member of Cable Car Capital LLC, an investment adviser he founded in 2013. Cable Car Capital LLC is the General Partner of Funicular Funds, LP, a hedge fund. From 2012 to 2013, Mr. MaWeaver was employed as an investment analyst at Amici Capital LLC, where he focused on healthcare. He was previously employed as an equity research associate at Dodge & Cox and a corporate finance business analyst at McKinsey & Company. Mr. Ma-Weaver received a Bachelor of Arts in Comparative Literature & Society and Economics and a Master of Arts in Statistics from Columbia University. He is a Chartered Financial Analyst (CFA) charterholder.
- Linda Grais
-
Linda Grais，自2007年5月起担任董事会成员。Grais博士自2008年1月起担任上市生物制药公司Ocera Therapeutics, Inc.的董事，并于2012年6月成为Ocera的总裁兼首席执行官，并一直担任该职务，直到Ocera于2017年12月被马林克罗制药收购。Grais博士在2005年5月至2011年2月期间担任风险投资公司InterWest Partners的管理成员。从1998年7月到2003年7月，Grais博士是一家药物发现公司SGX Pharmaceuticals Inc.的创始人和执行副总裁。在此之前，她是Wilson Sonsini Goodrich & Rosati的公司律师，在风险融资、公开发行和战略合作伙伴关系等领域执业。在从事法律工作之前，Grais博士曾在加州大学旧金山分校担任内科和重症监护的临床助理教授。Grais博士以优异成绩获得耶鲁大学学士学位，并获得耶鲁大学医学院医学博士学位和斯坦福大学法学院法学博士学位的Phi Beta Kappa。自2015年9月起，Grais博士担任PRA健康科学的董事会成员，该公司于2021年被公共合同研究机构ICON plc收购，目前担任ICON plc的董事会成员。Grais博士还于2019年1月加入上市制药公司Corvus制药的董事会，并于2023年3月加入私营医疗保健服务公司Collective Health的董事会。
Linda Grais,has served as a member of the Board of Directors since May 2007. Dr. Grais was a director of Ocera Therapeutics, Inc., a public biopharmaceutical company, since January 2008 and became President and Chief Executive Officer of Ocera in June 2012, and served in that role until Ocera's acquisition by Mallinckrodt Pharmaceuticals in December 2017. Dr. Grais served as a Managing Member at InterWest Partners, a venture capital firm from May 2005 until February 2011. From July 1998 to July 2003, Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. Dr. Grais received a B.A. from Yale University, magna cum laude, and Phi Beta Kappa, an M.D. from Yale Medical School and a J.D. from Stanford Law School. Since September 2015, Dr. Grais served on the board of PRA Health Sciences, which was acquired by ICON plc in 2021, a public contract research organization, and currently serves on the board of ICON plc. Dr. Grais also joined the board of Corvus Pharmaceuticals., a publicly traded pharmaceutical company, in January 2019, and joined the board of Collective Health, a private healthcare services company, in March 2023. - Linda Grais，自2007年5月起担任董事会成员。Grais博士自2008年1月起担任上市生物制药公司Ocera Therapeutics, Inc.的董事，并于2012年6月成为Ocera的总裁兼首席执行官，并一直担任该职务，直到Ocera于2017年12月被马林克罗制药收购。Grais博士在2005年5月至2011年2月期间担任风险投资公司InterWest Partners的管理成员。从1998年7月到2003年7月，Grais博士是一家药物发现公司SGX Pharmaceuticals Inc.的创始人和执行副总裁。在此之前，她是Wilson Sonsini Goodrich & Rosati的公司律师，在风险融资、公开发行和战略合作伙伴关系等领域执业。在从事法律工作之前，Grais博士曾在加州大学旧金山分校担任内科和重症监护的临床助理教授。Grais博士以优异成绩获得耶鲁大学学士学位，并获得耶鲁大学医学院医学博士学位和斯坦福大学法学院法学博士学位的Phi Beta Kappa。自2015年9月起，Grais博士担任PRA健康科学的董事会成员，该公司于2021年被公共合同研究机构ICON plc收购，目前担任ICON plc的董事会成员。Grais博士还于2019年1月加入上市制药公司Corvus制药的董事会，并于2023年3月加入私营医疗保健服务公司Collective Health的董事会。
- Linda Grais,has served as a member of the Board of Directors since May 2007. Dr. Grais was a director of Ocera Therapeutics, Inc., a public biopharmaceutical company, since January 2008 and became President and Chief Executive Officer of Ocera in June 2012, and served in that role until Ocera's acquisition by Mallinckrodt Pharmaceuticals in December 2017. Dr. Grais served as a Managing Member at InterWest Partners, a venture capital firm from May 2005 until February 2011. From July 1998 to July 2003, Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. Dr. Grais received a B.A. from Yale University, magna cum laude, and Phi Beta Kappa, an M.D. from Yale Medical School and a J.D. from Stanford Law School. Since September 2015, Dr. Grais served on the board of PRA Health Sciences, which was acquired by ICON plc in 2021, a public contract research organization, and currently serves on the board of ICON plc. Dr. Grais also joined the board of Corvus Pharmaceuticals., a publicly traded pharmaceutical company, in January 2019, and joined the board of Collective Health, a private healthcare services company, in March 2023.
- Michael R. Bristow
-
Michael R. Bristow，自2009年7月他一直担任公司的总裁兼首席执行官。在此之前，他担任本公司的首席科学与医疗官，自与Nuvelo合并董事。他还曾担任ARCA科罗拉多董事自2006年11月。他是科罗拉多方舟的创始人之一，在2004年9月，担任自该日起其主席及行政总裁，直到他被任命为位置首席科学与医疗官在2006年11月。他是医学教授，心内科在科罗拉多大学健康科学中心，在那里他一直自1991年10月大学前总目他是肌浆蛋白的创始人之一公司并担任肌浆蛋白的首席科学与医疗官从1996年10月至2006年2月，并作为科学顾问，肌浆蛋白从2006年2月直至资产的购肌浆蛋白由吉利德科学公司在2006年11月。他是一个合适的成员董事会给了他丰富的经验和专业知识，心脏病专家，医学研究者和心血管医学领域的药物开发，和心脏衰竭具体而言，他的经验作为心血管为重点，公共制药公司的创始人和管理者的公司董事会。他还拥有丰富的经验和知识，ARCA的业务，如ARCA科罗拉多州的创始人及前任首席科学与医疗官，和方舟的现任主席兼行政总裁，并作为ARCA科罗拉多的董事会成员，因为自2009年1月本公司2005年和。
Michael R. Bristow,was one of the founders of ARCA in September 2004, and has served as a Director since that time. Dr. Bristow has also served as the Company's President and Chief Executive Officer since July 2009. Previously, Dr. Bristow served as the President and Chief Executive Officer of the Company from September 2004 to November 2006, and as the Company's Chief Science and Medical Officer from November 2006 to July 2009. Dr. Bristow is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has been since October 1991. Dr. Bristow was one of the founders of Myogen, Inc. and served as Myogen's Chief Science and Medical Officer from October 1996 to February 2006 and as a Scientific Advisor to Myogen from February 2006 until the acquisition of Myogen by Gilead Sciences, Inc. in November 2006. Dr. Bristow holds a M.D. and Ph.D. from the University of Illinois. - Michael R. Bristow，自2009年7月他一直担任公司的总裁兼首席执行官。在此之前，他担任本公司的首席科学与医疗官，自与Nuvelo合并董事。他还曾担任ARCA科罗拉多董事自2006年11月。他是科罗拉多方舟的创始人之一，在2004年9月，担任自该日起其主席及行政总裁，直到他被任命为位置首席科学与医疗官在2006年11月。他是医学教授，心内科在科罗拉多大学健康科学中心，在那里他一直自1991年10月大学前总目他是肌浆蛋白的创始人之一公司并担任肌浆蛋白的首席科学与医疗官从1996年10月至2006年2月，并作为科学顾问，肌浆蛋白从2006年2月直至资产的购肌浆蛋白由吉利德科学公司在2006年11月。他是一个合适的成员董事会给了他丰富的经验和专业知识，心脏病专家，医学研究者和心血管医学领域的药物开发，和心脏衰竭具体而言，他的经验作为心血管为重点，公共制药公司的创始人和管理者的公司董事会。他还拥有丰富的经验和知识，ARCA的业务，如ARCA科罗拉多州的创始人及前任首席科学与医疗官，和方舟的现任主席兼行政总裁，并作为ARCA科罗拉多的董事会成员，因为自2009年1月本公司2005年和。
- Michael R. Bristow,was one of the founders of ARCA in September 2004, and has served as a Director since that time. Dr. Bristow has also served as the Company's President and Chief Executive Officer since July 2009. Previously, Dr. Bristow served as the President and Chief Executive Officer of the Company from September 2004 to November 2006, and as the Company's Chief Science and Medical Officer from November 2006 to July 2009. Dr. Bristow is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has been since October 1991. Dr. Bristow was one of the founders of Myogen, Inc. and served as Myogen's Chief Science and Medical Officer from October 1996 to February 2006 and as a Scientific Advisor to Myogen from February 2006 until the acquisition of Myogen by Gilead Sciences, Inc. in November 2006. Dr. Bristow holds a M.D. and Ph.D. from the University of Illinois.
- Robert E. Conway
-
Robert E. Conway，2013年9月被任命为董事会成员，自2014年起担任方舟生物医药公司董事会主席。Conway先生于1999年至2012年担任上市生物制药公司Array生物制药的首席执行官和董事会成员。在加入Array之前，Conway先生曾于1996年至1999年担任Hill Top Research，Inc.的首席运营官和执行副总裁。从1979年到1996年，Conway先生在康宁公司担任过多个行政职务，包括公司副总裁兼合同研究机构康宁 Hazleton，Inc.的总经理。2004年至2013年，他在PRA International，Inc.的董事会任职，该公司在其任职的部分时间内是一家上市公司，2012年至今，他在私营公司eResearch Technology，Inc.的董事会任职，2015年至2017年7月，Advarra，Inc.在2019年至2022年8月，他在Nivalis Therapeutics，Inc.的董事会任职，Nivalis Therapeutics，Inc.是一家上市、临床阶段制药公司。2017年7月，Nivalis Therapeutics，Inc.与Alpine Immune Sciences, Inc.（一家上市、临床阶段的制药公司）合并，Conway先生在此类合并后继续在董事会任职。此外，Conway先生是Genstar Capital，LLC的战略咨询委员会成员，也是Signant Health的董事会成员。2023年4月，Conway先生成为ClinOne，Inc.的执行董事长和董事会成员。Conway先生于1976年获得马凯特大学会计学学士学位。
Robert E. Conway,was appointed to the Board of Directors in September 2013, and has served as the Chairman of Arca Biopharma, Inc. Board of Directors since 2014. Mr. Conway served as the Chief Executive Officer and member of the board of directors of Array Biopharma, a publicly traded biopharmaceutical company, from 1999 to 2012. Prior to joining Array, Mr. Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999. From 1979 until 1996, Mr. Conway held various executive positions for Corning Inc. including Corporate Vice President and General Manager of Corning Hazleton, Inc., a contract research organization. From 2004 to 2013, he served on the board of directors of PRA International, Inc., which was a public company for a portion of his tenure there, from 2012 to the present, he has served on the board of directors of eResearch Technology, Inc., a private company, and from 2015 to July 2017, Advarra, Inc. from 2019 to August 2022, and he has served on the board of directors of Nivalis Therapeutics, Inc. a public, clinical stage pharmaceutical company. In July 2017, Nivalis Therapeutics, Inc. combined with Alpine Immune Sciences, Inc., a public, clinical stage pharmaceutical company, and Mr. Conway continues to serve on the board of directors following such combination. In addition, Mr. Conway is a member of the Strategic Advisory Committee of Genstar Capital, LLC and is a member of the board of directors of Signant Health. In April 2023, Mr. Conway became Executive Chairman and member of the board of directors of ClinOne, Inc. Mr. Conway received a B.S. in accounting from Marquette University in 1976. - Robert E. Conway，2013年9月被任命为董事会成员，自2014年起担任方舟生物医药公司董事会主席。Conway先生于1999年至2012年担任上市生物制药公司Array生物制药的首席执行官和董事会成员。在加入Array之前，Conway先生曾于1996年至1999年担任Hill Top Research，Inc.的首席运营官和执行副总裁。从1979年到1996年，Conway先生在康宁公司担任过多个行政职务，包括公司副总裁兼合同研究机构康宁 Hazleton，Inc.的总经理。2004年至2013年，他在PRA International，Inc.的董事会任职，该公司在其任职的部分时间内是一家上市公司，2012年至今，他在私营公司eResearch Technology，Inc.的董事会任职，2015年至2017年7月，Advarra，Inc.在2019年至2022年8月，他在Nivalis Therapeutics，Inc.的董事会任职，Nivalis Therapeutics，Inc.是一家上市、临床阶段制药公司。2017年7月，Nivalis Therapeutics，Inc.与Alpine Immune Sciences, Inc.（一家上市、临床阶段的制药公司）合并，Conway先生在此类合并后继续在董事会任职。此外，Conway先生是Genstar Capital，LLC的战略咨询委员会成员，也是Signant Health的董事会成员。2023年4月，Conway先生成为ClinOne，Inc.的执行董事长和董事会成员。Conway先生于1976年获得马凯特大学会计学学士学位。
- Robert E. Conway,was appointed to the Board of Directors in September 2013, and has served as the Chairman of Arca Biopharma, Inc. Board of Directors since 2014. Mr. Conway served as the Chief Executive Officer and member of the board of directors of Array Biopharma, a publicly traded biopharmaceutical company, from 1999 to 2012. Prior to joining Array, Mr. Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999. From 1979 until 1996, Mr. Conway held various executive positions for Corning Inc. including Corporate Vice President and General Manager of Corning Hazleton, Inc., a contract research organization. From 2004 to 2013, he served on the board of directors of PRA International, Inc., which was a public company for a portion of his tenure there, from 2012 to the present, he has served on the board of directors of eResearch Technology, Inc., a private company, and from 2015 to July 2017, Advarra, Inc. from 2019 to August 2022, and he has served on the board of directors of Nivalis Therapeutics, Inc. a public, clinical stage pharmaceutical company. In July 2017, Nivalis Therapeutics, Inc. combined with Alpine Immune Sciences, Inc., a public, clinical stage pharmaceutical company, and Mr. Conway continues to serve on the board of directors following such combination. In addition, Mr. Conway is a member of the Strategic Advisory Committee of Genstar Capital, LLC and is a member of the board of directors of Signant Health. In April 2023, Mr. Conway became Executive Chairman and member of the board of directors of ClinOne, Inc. Mr. Conway received a B.S. in accounting from Marquette University in 1976.
- Dan J. Mitchell
-
Dan J. Mitchell，于2014年2月被任命为董事会成员。他创立了Sequel Venture Partners，L.L.C.，这是一家成立于1997年1月的风险投资公司。在创立Sequel Venture Partners之前，Mitchell先生是Capital Health Venture Partners的创始人，这是一家专注于医疗保健的风险投资公司，他在1986年10月至2006年期间担任该公司的普通合伙人，并于1983年至1985年期间在芝加哥First National银行信托部的风险投资部门任职。他目前在几家私营公司的董事会任职。米切尔先生拥有伊利诺伊大学的学士学位和加州大学伯克利分校的工商管理硕士学位。
Dan J. Mitchell,was appointed to the Board of Directors in February 2014. He founded, and was a manager of Sequel Venture Partners, L.L.C., a venture capital firm formed in January 1997. Prior to founding Sequel Venture Partners, Mr. Mitchell was a founder of Capital Health Venture Partners, a health care focused venture capital firm, where he was a General Partner from October 1986 until 2006, and he was in the Venture Capital Division of the Trust Department of the First National Bank of Chicago from 1983 to 1985. He currently serves on the board of directors of several private companies. Mr. Mitchell holds a B.S. from the University of Illinois and an M.B.A. from the University of California at Berkeley. - Dan J. Mitchell，于2014年2月被任命为董事会成员。他创立了Sequel Venture Partners，L.L.C.，这是一家成立于1997年1月的风险投资公司。在创立Sequel Venture Partners之前，Mitchell先生是Capital Health Venture Partners的创始人，这是一家专注于医疗保健的风险投资公司，他在1986年10月至2006年期间担任该公司的普通合伙人，并于1983年至1985年期间在芝加哥First National银行信托部的风险投资部门任职。他目前在几家私营公司的董事会任职。米切尔先生拥有伊利诺伊大学的学士学位和加州大学伯克利分校的工商管理硕士学位。
- Dan J. Mitchell,was appointed to the Board of Directors in February 2014. He founded, and was a manager of Sequel Venture Partners, L.L.C., a venture capital firm formed in January 1997. Prior to founding Sequel Venture Partners, Mr. Mitchell was a founder of Capital Health Venture Partners, a health care focused venture capital firm, where he was a General Partner from October 1986 until 2006, and he was in the Venture Capital Division of the Trust Department of the First National Bank of Chicago from 1983 to 1985. He currently serves on the board of directors of several private companies. Mr. Mitchell holds a B.S. from the University of Illinois and an M.B.A. from the University of California at Berkeley.
- Raymond L. Woosley
-
Raymond L. Woosley，被任命为董事局ARCA 2013年7月。他是关键路径研究所C-路径目前的名誉主席，一个非营利性的，与联邦食品和药物管理局的公共 - 私营伙伴关系，其中他在2004年11月创办人，在那里他担任总裁，行政总裁兼董事会主席2005年至2011年。自2012年他也一直是亚利桑那中心教育与研究的董事治疗（AzCERT），一个独立的，非盈利研究和教育组织。自2001年以来他也一直医学和药理学教授在亚利桑那大学健康科学中心大学（UAHSC），并自2012年起名誉教授的，在那里他也为健康科学部副总裁2001至2005年和Dean医学院2001至2002年，从1988年至2001年他的医学在乔治城大学医学院，在那里他还心血管科学研究所所长1994至2000年和教授处长，临床药理学，中医学系1988年至1994年。他获得了博士学位在路易斯维尔和他的MD大学迈阿密大学药理学。他的研究已经发表在了265同行评审的出版物和50本书的章节。
Raymond L. Woosley,was appointed to the Board of Directors in July 2013. Since 2012, Dr. Woosley has been the Director of the Arizona Center for Education and Research on Therapeutics, an independent, nonprofit research and education organization. Dr. Woosley is currently the President Emeritus of the Critical Path Institute, a non-profit, public-private partnership with the Federal Food and Drug Administration, of which he was a founder in November 2004, and where he served as President, Chief Executive Officer and Chairman of the board of directors from 2005 to 2011. Since 2001, Dr. Woosley has also been a Professor of Medicine and Pharmacology at The University of Arizona Health Sciences Center, and, since 2012, Professor Emeritus, where he was also Vice President for Health Sciences from 2001 to 2005, and Dean of the College of Medicine from 2001 to 2002. Since 2015, he has been Professor of Medicine in the University of Arizona, College of Medicine-Phoenix. From 1988 to 2001, Dr. Woosley was a professor of medicine at the Georgetown University School of Medicine, where he was also Director of the Institute of Cardiovascular Sciences from 1994 to 2000, and Division Chief, Clinical Pharmacology, in the Department of Medicine from 1988 to 1994. Dr. Woosley earned his Ph.D. in Pharmacology from the University of Louisville and his M.D. from the University of Miami. - Raymond L. Woosley，被任命为董事局ARCA 2013年7月。他是关键路径研究所C-路径目前的名誉主席，一个非营利性的，与联邦食品和药物管理局的公共 - 私营伙伴关系，其中他在2004年11月创办人，在那里他担任总裁，行政总裁兼董事会主席2005年至2011年。自2012年他也一直是亚利桑那中心教育与研究的董事治疗（AzCERT），一个独立的，非盈利研究和教育组织。自2001年以来他也一直医学和药理学教授在亚利桑那大学健康科学中心大学（UAHSC），并自2012年起名誉教授的，在那里他也为健康科学部副总裁2001至2005年和Dean医学院2001至2002年，从1988年至2001年他的医学在乔治城大学医学院，在那里他还心血管科学研究所所长1994至2000年和教授处长，临床药理学，中医学系1988年至1994年。他获得了博士学位在路易斯维尔和他的MD大学迈阿密大学药理学。他的研究已经发表在了265同行评审的出版物和50本书的章节。
- Raymond L. Woosley,was appointed to the Board of Directors in July 2013. Since 2012, Dr. Woosley has been the Director of the Arizona Center for Education and Research on Therapeutics, an independent, nonprofit research and education organization. Dr. Woosley is currently the President Emeritus of the Critical Path Institute, a non-profit, public-private partnership with the Federal Food and Drug Administration, of which he was a founder in November 2004, and where he served as President, Chief Executive Officer and Chairman of the board of directors from 2005 to 2011. Since 2001, Dr. Woosley has also been a Professor of Medicine and Pharmacology at The University of Arizona Health Sciences Center, and, since 2012, Professor Emeritus, where he was also Vice President for Health Sciences from 2001 to 2005, and Dean of the College of Medicine from 2001 to 2002. Since 2015, he has been Professor of Medicine in the University of Arizona, College of Medicine-Phoenix. From 1988 to 2001, Dr. Woosley was a professor of medicine at the Georgetown University School of Medicine, where he was also Director of the Institute of Cardiovascular Sciences from 1994 to 2000, and Division Chief, Clinical Pharmacology, in the Department of Medicine from 1988 to 1994. Dr. Woosley earned his Ph.D. in Pharmacology from the University of Louisville and his M.D. from the University of Miami.
高管简历
中英对照 | 中文 | 英文- Thomas A. Keuer
Thomas A. Keuer自2014年12月以来担任公司的首席运营官。他自2006年以来担任公司制药业务的执行副总裁。在加入公司之前，他从2004年到2006年担任Insmed, Inc.运营高级副总裁。在Insmed之前，他从1998年到2004年担任Baxter Healthcare工程的副总裁。在Baxter之前，他担任Somatogen, Inc.运营的副总裁。他获得Rice University的化工程硕士学位和the University of Texas, Austin的化学工程学士学位。
Thomas A. Keuer,has served as the Company's Chief Operating Officer since December 2014. Mr. Keuer served as the Company's Executive Vice President, Pharmaceutical Operations from 2006 to 2014. Prior to joining the Company, Mr. Keuer served as the SVP of Operations for Insmed, Inc. from 2004 to 2006. Prior to Insmed, Mr. Keuer served as the VP of Engineering for Baxter Healthcare from 1998 to 2004. Prior to Baxter, Mr. Keuer served as the VP of Operations for Somatogen, Inc. Mr. Keuer received his M.S. in Biochemical Engineering from Rice University and received his B.S. in Chemical Engineering from the University of Texas, Austin.- Thomas A. Keuer自2014年12月以来担任公司的首席运营官。他自2006年以来担任公司制药业务的执行副总裁。在加入公司之前，他从2004年到2006年担任Insmed, Inc.运营高级副总裁。在Insmed之前，他从1998年到2004年担任Baxter Healthcare工程的副总裁。在Baxter之前，他担任Somatogen, Inc.运营的副总裁。他获得Rice University的化工程硕士学位和the University of Texas, Austin的化学工程学士学位。
- Thomas A. Keuer,has served as the Company's Chief Operating Officer since December 2014. Mr. Keuer served as the Company's Executive Vice President, Pharmaceutical Operations from 2006 to 2014. Prior to joining the Company, Mr. Keuer served as the SVP of Operations for Insmed, Inc. from 2004 to 2006. Prior to Insmed, Mr. Keuer served as the VP of Engineering for Baxter Healthcare from 1998 to 2004. Prior to Baxter, Mr. Keuer served as the VP of Operations for Somatogen, Inc. Mr. Keuer received his M.S. in Biochemical Engineering from Rice University and received his B.S. in Chemical Engineering from the University of Texas, Austin.
- Michael R. Bristow
Michael R. Bristow，自2009年7月他一直担任公司的总裁兼首席执行官。在此之前，他担任本公司的首席科学与医疗官，自与Nuvelo合并董事。他还曾担任ARCA科罗拉多董事自2006年11月。他是科罗拉多方舟的创始人之一，在2004年9月，担任自该日起其主席及行政总裁，直到他被任命为位置首席科学与医疗官在2006年11月。他是医学教授，心内科在科罗拉多大学健康科学中心，在那里他一直自1991年10月大学前总目他是肌浆蛋白的创始人之一公司并担任肌浆蛋白的首席科学与医疗官从1996年10月至2006年2月，并作为科学顾问，肌浆蛋白从2006年2月直至资产的购肌浆蛋白由吉利德科学公司在2006年11月。他是一个合适的成员董事会给了他丰富的经验和专业知识，心脏病专家，医学研究者和心血管医学领域的药物开发，和心脏衰竭具体而言，他的经验作为心血管为重点，公共制药公司的创始人和管理者的公司董事会。他还拥有丰富的经验和知识，ARCA的业务，如ARCA科罗拉多州的创始人及前任首席科学与医疗官，和方舟的现任主席兼行政总裁，并作为ARCA科罗拉多的董事会成员，因为自2009年1月本公司2005年和。
Michael R. Bristow,was one of the founders of ARCA in September 2004, and has served as a Director since that time. Dr. Bristow has also served as the Company's President and Chief Executive Officer since July 2009. Previously, Dr. Bristow served as the President and Chief Executive Officer of the Company from September 2004 to November 2006, and as the Company's Chief Science and Medical Officer from November 2006 to July 2009. Dr. Bristow is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has been since October 1991. Dr. Bristow was one of the founders of Myogen, Inc. and served as Myogen's Chief Science and Medical Officer from October 1996 to February 2006 and as a Scientific Advisor to Myogen from February 2006 until the acquisition of Myogen by Gilead Sciences, Inc. in November 2006. Dr. Bristow holds a M.D. and Ph.D. from the University of Illinois.- Michael R. Bristow，自2009年7月他一直担任公司的总裁兼首席执行官。在此之前，他担任本公司的首席科学与医疗官，自与Nuvelo合并董事。他还曾担任ARCA科罗拉多董事自2006年11月。他是科罗拉多方舟的创始人之一，在2004年9月，担任自该日起其主席及行政总裁，直到他被任命为位置首席科学与医疗官在2006年11月。他是医学教授，心内科在科罗拉多大学健康科学中心，在那里他一直自1991年10月大学前总目他是肌浆蛋白的创始人之一公司并担任肌浆蛋白的首席科学与医疗官从1996年10月至2006年2月，并作为科学顾问，肌浆蛋白从2006年2月直至资产的购肌浆蛋白由吉利德科学公司在2006年11月。他是一个合适的成员董事会给了他丰富的经验和专业知识，心脏病专家，医学研究者和心血管医学领域的药物开发，和心脏衰竭具体而言，他的经验作为心血管为重点，公共制药公司的创始人和管理者的公司董事会。他还拥有丰富的经验和知识，ARCA的业务，如ARCA科罗拉多州的创始人及前任首席科学与医疗官，和方舟的现任主席兼行政总裁，并作为ARCA科罗拉多的董事会成员，因为自2009年1月本公司2005年和。
- Michael R. Bristow,was one of the founders of ARCA in September 2004, and has served as a Director since that time. Dr. Bristow has also served as the Company's President and Chief Executive Officer since July 2009. Previously, Dr. Bristow served as the President and Chief Executive Officer of the Company from September 2004 to November 2006, and as the Company's Chief Science and Medical Officer from November 2006 to July 2009. Dr. Bristow is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has been since October 1991. Dr. Bristow was one of the founders of Myogen, Inc. and served as Myogen's Chief Science and Medical Officer from October 1996 to February 2006 and as a Scientific Advisor to Myogen from February 2006 until the acquisition of Myogen by Gilead Sciences, Inc. in November 2006. Dr. Bristow holds a M.D. and Ph.D. from the University of Illinois.
- C. Jeffrey Dekker
C. Jeffrey Dekker，注册会计师，自2011年10月起担任财务副总裁兼司库。自2012年3月起担任秘书。2006年2月加入公司，担任财务高级总监。在加入公司之前，在三个私人软件公司担任财务和会计领导职务，包括从2004年10月至2006年2月担任Webroot Software Inc.的总监，从1999年8月至2004年10月担任Requisite Technology Inc.的副总裁兼总监，1993年7月至1999年8月担任NxTrend Technology, Inc的副总裁和财务总监。从1989年7月至1993年7月在华盛顿州安吉利斯港的ITT Rayonier Port Angeles Pulp Division任职，最近担任经理和总会计。从1986年9月至1989年7月，他在毕马威国际会计公司任职，最近担任高级会计师。获得了犹他州立大学的会计学士学位，是一名注册会计师。
C. Jeffrey Dekker,has served as the Company's Chief Financial Officer and Treasurer since May 2021 and the Company's Secretary since April 2023. Prior to joining the Company, Mr. Dekker served in multiple roles of increasing responsibility at GlobeImmune, Inc. from 2006 to 2021, including President, Vice President of Finance, and Senior Director, Finance and Controller. Before joining GlobeImmune, Mr. Dekker held leadership positions in finance and accounting at private software companies since 1993, including posts ranging from Corporate Controller to Vice President at Webroot Software Inc., Requisite Technology Inc. and NxTrend Technology Inc. Earlier in his career, Mr. Dekker worked at ITT Rayonier Port Angeles Pulp Division and at KPMG in Los Angeles. He earned a B.S. in accounting from Utah State University and is a certified public accountant.- C. Jeffrey Dekker，注册会计师，自2011年10月起担任财务副总裁兼司库。自2012年3月起担任秘书。2006年2月加入公司，担任财务高级总监。在加入公司之前，在三个私人软件公司担任财务和会计领导职务，包括从2004年10月至2006年2月担任Webroot Software Inc.的总监，从1999年8月至2004年10月担任Requisite Technology Inc.的副总裁兼总监，1993年7月至1999年8月担任NxTrend Technology, Inc的副总裁和财务总监。从1989年7月至1993年7月在华盛顿州安吉利斯港的ITT Rayonier Port Angeles Pulp Division任职，最近担任经理和总会计。从1986年9月至1989年7月，他在毕马威国际会计公司任职，最近担任高级会计师。获得了犹他州立大学的会计学士学位，是一名注册会计师。
- C. Jeffrey Dekker,has served as the Company's Chief Financial Officer and Treasurer since May 2021 and the Company's Secretary since April 2023. Prior to joining the Company, Mr. Dekker served in multiple roles of increasing responsibility at GlobeImmune, Inc. from 2006 to 2021, including President, Vice President of Finance, and Senior Director, Finance and Controller. Before joining GlobeImmune, Mr. Dekker held leadership positions in finance and accounting at private software companies since 1993, including posts ranging from Corporate Controller to Vice President at Webroot Software Inc., Requisite Technology Inc. and NxTrend Technology Inc. Earlier in his career, Mr. Dekker worked at ITT Rayonier Port Angeles Pulp Division and at KPMG in Los Angeles. He earned a B.S. in accounting from Utah State University and is a certified public accountant.